Faron Pharmaceuticals Ltd

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
Clever-1Monoclonal antibody
Non-Small Cell Lung CancerAcute Myeloid LeukemiaMyelodysplastic Syndromes
Higher-Risk Myelodysplastic Syndromes

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
BexmarilimabPhase 1/2Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
Est. primary completion 2027-03 · NCT05428969 · CT.gov ↗
What to watch
November 2027 (1)
BexmarilimabPhase 2Higher Risk Myelodysplastic Syndromes
Est. primary completion 2027-11 · NCT07672769 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (4)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$0$7.8M$16M—report ↗

Faron reported revenue of $0M, unchanged YoY, with R&D spend of $7.77M, up 7.8% YoY, and cash and equivalents of $15.87M. The company posted an operating loss of EUR 11.9 million for H1 2025 and a loss per share of EUR 0.18; net income was not disclosed.

Faron does not provide a short-term outlook. During the period, bexmarilimab progressed with full enrollment of the BEXMAB phase II dose optimization and phase I/II frontline HR-MDS studies, positive phase II efficacy data presented at major oncology congresses, and publication of phase I BEXMAB data in Lancet Haematology. EMA and FDA granted orphan drug designation for bexmarilimab in MDS. After period end, FDA end-of-phase II feedback supported advancement into a registrational phase II/III study in frontline HR-MDS with CR+CReq as primary and overall survival as co-primary endpoints. Financially, an oversubscribed EUR 12M private placement and an up to EUR 35M convertible bond arrangement (first tranche EUR 15M) extended the cash runway into Q1 2026.

View 3 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-H1$0$7.2M$32M—report ↗
2023-H1$0$9.2M$6.9M—report ↗
2022-H1$0$11M$10M—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$14M$14M—report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$13M$9.9M—report ↗
2023-FY$0$21M$7.6M—report ↗
2022-FY$0$22M$7.5M—report ↗
2021-FY$0$21M$7.8M—report ↗